Icon (ICLR) Total Non-Current Liabilities (2009 - 2026)
Icon's (ICLR) quarterly Total Non-Current Liabilities came in at $6.9 billion in Q2 2026, little changed year-over-year from $7.0 billion in Q2 2025, and little changed quarter-over-quarter from $6.9 billion in Q1 2026.
Analysis
Icon (ICLR) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Total Non-Current Liabilities for 18 consecutive years, with $6.9 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities changed 0.08% year-over-year to $6.9 billion in Q2 2026; TTM through Jun 2026 was $6.9 billion, a 0.08% change from a year earlier, with the FY2025 full-year figure at $3.8 billion, down 14.78% from the prior year.
- Total Non-Current Liabilities was $6.9 billion for Q2 2026 at Icon, roughly flat from $6.9 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $9.1 billion in Q1 2022 and troughed at $3.8 billion in Q4 2025.
- A 5-year average of $7.1 billion and a median of $7.2 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 478.58% in 2022 and slumped 47.12% in 2024, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $5.8 billion in 2022, then surged by 34.61% to $7.7 billion in 2023, then slumped by 42.84% to $4.4 billion in 2024, then retreated by 14.78% to $3.8 billion in 2025, then jumped by 83.98% to $6.9 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $6.9 billion (Q2 2026), $6.9 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 22.94 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 1.56 Bn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 6.94 Bn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 4.24 Bn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 2.15 Bn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 30.49 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 553.39 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 28.62 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.94 Bn |
| Mar 31, 2026 | 6.95 Bn |
| Dec 31, 2025 | 3.77 Bn |
| Sep 30, 2025 | 7.07 Bn |
| Jun 30, 2025 | 6.95 Bn |
| Mar 31, 2025 | 7.14 Bn |
| Dec 31, 2024 | 4.43 Bn |
| Sep 30, 2024 | 7.39 Bn |
| Jun 30, 2024 | 7.34 Bn |
| Mar 31, 2024 | 4.54 Bn |
| Dec 31, 2023 | 7.75 Bn |
| Sep 30, 2023 | 8.03 Bn |
| Jun 30, 2023 | 8.27 Bn |
| Mar 31, 2023 | 8.59 Bn |
| Dec 31, 2022 | 5.76 Bn |
| Sep 30, 2022 | 8.85 Bn |
| Jun 30, 2022 | 8.85 Bn |
| Mar 31, 2022 | 9.06 Bn |
| Dec 31, 2021 | 6.66 Bn |
| Sep 30, 2021 | 9.61 Bn |